Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

146 citing papers in PubMed, 5 syntheses or guidelines pooled it, 230 citations in OpenAlex.

1. Ascertaining the mechanistic etiology of COVID-associated glomerulonephritis: a systematic review.Frontiers in medicine · 2025
   Pooled it
2. Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.Vaccine · 2023
   Pooled it
3. Antibody titers of individuals vaccinated for COVID-19: A systematic review.Journal of biosciences · 2023
   Pooled it
4. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis.BMJ (Clinical research ed.) · 2022
   Pooled it
5. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.Infectious diseases of poverty · 2022
   Pooled it
6. Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women.Human vaccines & immunotherapeutics · 2023
   Trial
7. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.Cell reports. Medicine · 2023
   Trial
8. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.Human vaccines & immunotherapeutics · 2022
   Trial
9. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.Journal of the Formosan Medical Association = Taiwan yi zhi · 2022
   Trial
10. Safety and immunogenicity of a first-generation modified vaccinia virus Ankara-vectored SARS-CoV-2 vaccine candidate with mRNA-based booster vaccination: A phase 1 trial.Human vaccines & immunotherapeutics · 2026
    Article
11. Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates.EBioMedicine · 2026
    Article
12. Comparison of Immune Responses and Safety Profiles Following a Fourth Heterologous Dose (Second Booster) with mRNA-1273 in Individuals Previously Vaccinated with Two Doses of CoronaVac and a Booster Dose of Either AZD1222 or BNT162b2.Vaccines · 2026
    Article
13. Systematic profiling of SARS-CoV-2 structural protein-specific T cell epitopes in Omicron infections following inactivated vaccination.iScience · 2026
    Article
14. The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost.Science translational medicine · 2026
    Article
15. Durability of COVID-19 vaccine-induced immunity in Saudi Arabia: evidence, gaps, and implications for Hajj and mass-gathering preparedness.Frontiers in public health · 2026
    Review
16. Longitudinal SARS-CoV-2 Antibody Response in Healthcare Workers: Benefit of Prior Infection and Heterologous Boosting on Anti-Spike IgG Immunity.Influenza and other respiratory viruses · 2026
    Observational
17. Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses.Vaccines · 2025
    Review
18. Serological Response to COVID-19 Vaccination in Saudi Arabia: A Comparative Study of IgG and Neutralising Antibodies Across Vaccine Platforms.Vaccines · 2025
    Article
19. Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach.Vaccines · 2025
    Review
20. Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens.Scientific reports · 2025
    Article

86 more citing papers are in PubMed but not listed here.

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

26 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as